Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Revenue: 2020-2024

Historic Revenue for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $203.1 million.

  • Xeris Biopharma Holdings' Revenue rose 37.06% to $74.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.1 million, marking a year-over-year increase of 42.05%. This contributed to the annual value of $203.1 million for FY2024, which is 23.89% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Revenue of $203.1 million as of FY2024, which was up 23.89% from $163.9 million recorded in FY2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Revenue peaked at $203.1 million during FY2024, and registered a low of $20.4 million during FY2020.
  • For the 3-year period, Xeris Biopharma Holdings' Revenue averaged around $159.1 million, with its median value being $163.9 million (2023).
  • Data for Xeris Biopharma Holdings' Revenue shows a peak YoY skyrocketed of 142.67% (in 2021) over the last 5 years.
  • Xeris Biopharma Holdings' Revenue (Yearly) stood at $20.4 million in 2020, then surged by 142.67% to $49.6 million in 2021, then spiked by 122.32% to $110.2 million in 2022, then skyrocketed by 48.68% to $163.9 million in 2023, then grew by 23.89% to $203.1 million in 2024.